Study in Patients With Asthma
NCT00215397 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2010-11-11
Summary
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective in the treatment of asthma compared to the control drug.
Conditions
Interventions
- DRUG
-
Formoterol Fumarate
Sponsors & Collaborators
-
Dey
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 5 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Primary Completion
- 2003-02-28
- Completion
- 2005-12-31
Countries
- United States
Study Locations
More Related Trials
-
A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects
NCT00583947 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
NCT01436071 ·Status: COMPLETED ·Phase: PHASE3
-
A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma
NCT00130351 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma
NCT00393991 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents
NCT01431950 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Mild Asthmatic Patients
NCT00748306 ·Status: COMPLETED ·Phase: PHASE2
-
Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol
NCT02491970 ·Status: TERMINATED ·Phase: PHASE4
-
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
NCT00394121 ·Status: COMPLETED ·Phase: PHASE3
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
NCT01225913 ·Status: RECRUITING ·Phase: PHASE4
-
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma
NCT00394199 ·Status: COMPLETED ·Phase: PHASE3
-
A 12-Week Study in Adult Subjects With Asthma
NCT01516086 ·Status: COMPLETED ·Phase: PHASE2
-
12-Week Study in Adult Subjects With Asthma
NCT01516073 ·Status: COMPLETED ·Phase: PHASE2
-
Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients
NCT00358488 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
NCT01085474 ·Status: COMPLETED
-
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma
NCT00393952 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma
NCT02127697 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study to Evaluate GSK2190915 in Subjects With Mild Asthma
NCT00812773 ·Status: COMPLETED ·Phase: PHASE2
-
GSK2190915 Moderate to Severe Asthma Study
NCT00850642 ·Status: TERMINATED ·Phase: PHASE2
-
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
NCT03086460 ·Status: COMPLETED ·Phase: PHASE2
-
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
NCT01537133 ·Status: COMPLETED ·Phase: NA
-
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
NCT01197794 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics
NCT00150397 ·Status: COMPLETED ·Phase: PHASE2
-
Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)
NCT00092144 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)
NCT01566149 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacodynamic/Pharmacokinetic Interactions Between Oral Roflumilast and Inhaled Formoterol
NCT00940329 ·Status: COMPLETED ·Phase: PHASE1